The financing will go toward further development of Klaris' phenotypic single-cell technology that can rapidly identify pathogens and determine their response to antibiotics.
Participants in the financing round included CS Investors, Pivotal Paramount Investment, and Stanford University.
The firm said that its technology enables the detection of rare DNA variants with high accuracy to enable liquid biopsy diagnosis and treatments for multiple diseases.
The company will use the funding to advance the commercialization of its proprietary liquid biopsy technology.
The financing will go toward development of the company's home-based testing technology, which will be initially targeted at fertility testing.
The firm also offers an NIPT, codeveloped with Yale, that its CEO said is differentiated by its rapid time-to-result.
LetsGetChecked's platform allows patients to order physician-approved lab tests, and then send their samples to the company for analysis and test results.
The firm plans to use the financing to extend its portfolio of point-of-care IVD tests for critical care and emergency medicine.
It will use the funds to help expand the development and commercialization of its non-invasive genetic tests for early-stage cancer detection.
Illumina Ventures was the sole investor in the Series A1 round, which will go toward Cernostics' clinical and market development studies for its TissueCypher Barrett's Esophagus assay.